Genetic polymorphisms in MTHFR (C677T, A1298C), MTR (A2756G) and MTRR (A66G) genes associated with pathological characteristics of prostate cancer in the ecuadorian population

American Journal of the Medical Sciences

Volumn 346, Issue 6, 2013, Pages 447-454

  López Cortés, Andrés ^a   Jaramillo Koupermann, Gabriela ^a   Muñoz, María J ^a   Cabrera, Alejandro ^a   Echeverría, Carolina ^a   Rosales, Felipe ^b   Vivar, Nicolás ^c   Paz Y Miño, César ^a  

^a UNIVERSIDAD DE LAS AMÉRICAS   (Ecuador)

^b Hospital Solon Espinoza Ayala   (Ecuador)

^c HOSPITAL CARLOS ANDRADE MARÍN   (Ecuador)

Author keywords

Ecuadorian population; MTHFR; MTR; MTRR; Prostate cancer

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); METHIONINE SYNTHASE; METHIONINE SYNTHASE REDUCTASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; DNA DAMAGE; DNA METHYLATION; DNA SYNTHESIS; ECUADOR; ENZYME ACTIVITY; FOLATE METABOLISM; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

EID: 84890858584     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3182882578     Document Type: Article

References (50)

1. Jemal A, Bray F, Center M, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
2. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36
3. American Cancer Society. Cancer Facts & Figures 2011. Atlanta, GA: American Cancer Society, 2011
4. Ferlay J, Shin H, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
5. Cueva P, Yépez J. Cancer Epidemiology in Quito 2003-2005. Quito, Equador: National Cancer Registry (NCR), SOLCA; 2009
6. Bai J, Zheng M, Xia X, et al. MTHFR C677T polymorphism contributes to prostate cancer risk among Caucasians: A meta-analysis of 3511 cases and 2762 controls. Eur J Cancer 2009;45:1443-9
7. Muslumanoglu M, Tepeli E, Demir S, et al. The analysis of the relationship between A1298C and C677T polymorphisms of the MTHFR gene with prostate cancer in Eskisehir population. Genet Test Mol Biomarkers 2009;13:641-5
8. Cicek M, Nock N, Conti D, et al. Relationship between methylenetetrahydrofolate reductase C677T and A1298C genotypes and haplotypes and prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 2004;13:1331-6
9. Singal R, Ferdinand L, Das P, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk. Int J Oncol 2004;25:1465-71
10. Michael S, Qamar R, Akhat F, et al. C677T polymorphism in the methylenetetrahydrofolate reductase gene is associated with primary closed angle glaucoma. Mol Vis 2008;14:661-665
11. Hubner R, Muir K, Lui J, et al. Folate metabolism polymorphisms influence risk of colorectal adenoma recurrence. Cancer Epidemiol Biomarkers Prev 2006;15:1607-13
12. Heijmans B, Boer J, Suchiman E, et al. A common variant of the methylenetetrahydrofolate reductase gene (1q36) is associated with an increased risk of cancer. Cancer Res 2003;63:1249-53
13. Wilson A, Platt R, Wu Q, et al. A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol Genet Metab 1999;67:317-23
14. Johansson M, Van Guelpen B, Hutdin J, et al. The MTHFR C677 -. T polymorphism and risk of prostate cancer: Results from the CAPS study. Cancer Causes Cont 2007;18:1169-74
15. Hobbs C, Sherman S, Yi P, et al. Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome. Am J Hum Genet 2000;67:623-30
16. Dhillon V, Thomas P, Fenech M. Effect of common polymorphisms in folate uptake and metabolism genes on frequency of micronucleated lymphocytes in a South Australian cohort. Mutant Res 2009;665:1-6
17. Ulvik A, Ueland P. Single nucleotide polymorphism (SNP) genotyping in unprocessed whole blood and serum by real-time PCR: Application to SNPs affecting homocysteine and folate metabolism. Clin Chem 2001;47:2050-3
18. Bailey L, Gregory J, III. Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: Metabolic significance, risks and impact on folate requirement. J Nutr 1999;129:919-22
19. Das P, Signal R. DNA methylation and cancer. J Clin Oncol 2004;22: 4632-42
20. Gershoni-Baruch R, Dagan E, Israeli D. Association of the C677T polymorphism in the MTHFR gene with breast and/or ovarian cancer risk in Jewish women. Eur J Cancer 2000;36:2313-6
21. Song C, Xing D, Tan W. Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res 2001;61:3272-5
22. Miao X, Xing D, Tan W. Susceptibility to gastric cardia adenocarcinoma and genetic polymorphisms in methylenetetrahydrofolate reductase in an at-risk Chinese population. Cancer Epidemiol Biomarkers Prev 2002;11:1454-8
23. Kimura F, Franke K, Steinhoff C, et al. Methyl group metabolism gene polymorphisms and susceptibility to prostatic carcinoma. Prostate 2000;45:225-31
24. Wiemels J, Smith R, Taylor G. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci U S A 2001;98: 4004-9
25. Chen J, Giovannucci E, Kelsey K. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996; 56:4862-4
26. Chen J, Stampfer M, Ma J. Influence of a methionine synthase (D919G) polymorphism on plasma homocysteine and folate levels and relation to risk of myocardial infarction. Atherosclerosis 2001; 154:667-672
27. Olteanu H, Munson T, Banerjee R. Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry 2002;41:13378-85
28. Humphrey P. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004;17:292-306
29. Vickers A, Lilja H. Prostate cancer: Estimating the benefits of PSA screening. Nat Rev Urol 2009;6:301-303
30. Zhang Z, Shi Q, Liu Z, et al. Polymorphisms of methionine synthase and methionine synthase reductase and risk of squamous cell carcinoma of the head and neck: A case-control analysis. Cancer Epidemiol Biomarkers Prev 2005;14:1188-93
31. Ueland P, Hustad S, Schneede J, et al. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001;22:195-201
32. Chen J, Giovannucci E, Hankinson S, et al. A prospective study of methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms, and risk of colorectal adenoma. Carcinogenesis 1998; 19:2129-32
33. Pereira T, Rudnicki M, Pereira A, et al. 5,10-Methylenetetrahydrofolate reductase polymorphisms and acute lymphoblastic leukemia risk: A meta-analysis. Cancer Epidemiol Biomark Prev 2006; 15:1956-63
34. Yegnasubramanian S, Kowalski J, Gonzalo M, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975-86
35. Sharp L, Little J. Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: A HuGE review. Am J Epidemiol 2004; 159:423-43
36. Robien K, Ulrich C. 5, 10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: A HuGE minireview. Am J Epidemiol 2003;157:571-82
37. Shen H, Xu Y, Zheng Y, et al. Polymorphisms of 5,10- methylenetetrahydrofolate reductase and risk of gastric cancer in a Chinese population: A case-control study. Int J Cancer 2001;95:332-6
38. Marchal C, Redondo M, Reyes-Engel A, et al. Association between polymorphisms of folate-metabolizing enzymes and risk of prostate cancer. Eur J Surg Oncol 2008;34:805-10
39. Guelpen B, Wiren S, Bergh A, et al. Polymorphisms of methylenetetrahydrofolate reductase and the risk of prostate cancer: A nested casecontrol study. Eur J Cancer Prev 2006;15:46-50
40. Esteller M, García A, Martinez-Palones J, et al. Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis 1997;18:2307-11
41. Sharp L, Little J, Schofield A, et al. Folate and breast cancer: The role of polymorphisms in methylenetetrahydrofolate reductase (MTHFR). Cancer Lett 2002;181:65-71
42. Schrubsole M, Gao T, Cai Q, et al. MTR and MTRR polymorphisms, dietary intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:586-8
43. Matsuo K, Suzuki R, Hamajina N, et al. Methionine synthase reductase gene A66G polymorphism is associated with risk of colorectal cancer. Asian Pac J Cancer Prev 2002;3:353-9
44. De Re V, Cannizzaro R, Canzonieri V, et al. MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancer. Tumour Biol 2010;31:23-32
45. Paz-y-Miño C, López-Cortés A, Muñoz MJ, et al. Incidence of the L858R and G719S mutations of the epidermal growth factor receptor oncogene in an Ecuadorian population with lung cancer. Cancer Genet Cytogenet 2010;196:201-3
46. Paz-y-Miño C, Muñoz MJ, López-Cortés A, et al. Frequency of polymorphisms pro198leu in GPX-1 gene and ile58thr in MnSOD gene in the altitude Ecuadorian population with bladder cancer. Oncol Res 2010;18:395-400
47. Paz-y-Miño C, Witte T, Robles P, et al. Association among polymorphisms in the steroid 5a-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumours in an Ecuadorian population. Cancer Genet Cytogenet 2009;189:71-6
48. Paz-y-Miño C, Pérez J, Fiallo B, et al. A polymorphism in the hMSH2 gene (gIVS12-6T-C) associated with non-Hodgkin lymphomas. Cancer Genet Cytogenet 2002;133:29-33
49. Paz-y-Miño C, Leone PE. Three novel somatic mutations in the NF2 tumor suppressor gene (g816T.A; g1159A.G; gIVS11-1G.T). Hum Mutat 2000;15:487
50. Paz-y-Miño C, López-Cortés A, Muñoz MJ, et al. Relationship of a hRAD54 gene polymorphism (2290 C/T) in an Ecuadorian population with chronic myelogenous leukemia. Genet Mol Biol 2010;33: 646-9